Previous 10 | Next 10 |
Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development First two programs include a program in acute myeloid leukemia and a p...
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will pres...
Gainers: PyroGenesis Canada (NASDAQ:PYR) +72%. Microbot Medical MBOT +50%. CollPlant Biotechnologies CLGN +32%. Future FinTech FTFT +41%. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. Spruce Biosciences (NASDAQ:SPRB) +31%. Tarena International TEDU +19%. CNF...
Harmony Biosciences Holdings (NASDAQ:HRMY), Aquestive Therapeutics (NASDAQ:AQST), C4 Therapeutics (NASDAQ:CCCC), Century Therapeutics (NASDAQ:IPSC), COMPASS Pathways (NASDAQ:CMPS) have been added to the Nasdaq Biotechnology Index. All the additions will be effective prior to market ...
PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced it has been selected for addition to the NASDAQ Biotechnolo...
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma; IND submission on track for mid-2022 - ...
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have participate...
Century Therapeutics (NASDAQ:IPSC): Q3 GAAP EPS of -$0.48 misses by $0.08. Cash, cash equivalents, and marketable securities were $400.3M Press Release For further details see: Century Therapeutics EPS misses by $0.08
Lead program, CNTY-101 in relapsed/refractory non-Hodgkin’s lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be presented at the ASH Annual Meeting Research and development update to be held ...
PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s CNTY-101 pr...
News, Short Squeeze, Breakout and More Instantly...
Century Therapeutics Inc. Company Name:
IPSC Stock Symbol:
NASDAQ Market:
Century Therapeutics Inc. Website:
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA m...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD30...
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoim...